Stereoselectivity by enantiomeric inhibitors of matrix metalloproteinase-8: New insights from molecular dynamics simulations

Journal of Medicinal Chemistry

Volumn 50, Issue 2, 2007, Pages 211-218

  Aschi, Massimiliano ^a   Besker, Neva ^b   Re, Nazzareno ^b   Pochetti, Giorgio ^c   Coletti, Cecilia ^b   Gallina, Carlo ^b   Mazza, Fernando ^a,c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c C N R   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

[1 (4' METHOXYBIPHENYL 4 SULFONYLAMINO) 2 METHYLPROPYL]PHOSPHONATE; MATRIX METALLOPROTEINASE 8 INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PROTEIN; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; BINDING AFFINITY; CONFORMATION; ENANTIOMER; ENANTIOSELECTIVITY; ENTROPY; ENZYME ACTIVE SITE; MOLECULAR DYNAMICS; STEREOCHEMISTRY; X RAY CRYSTALLOGRAPHY;

CATALYTIC DOMAIN; ENTROPY; MATRIX METALLOPROTEINASE 8; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHOSPHONIC ACIDS; PROTEASE INHIBITORS; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STEREOISOMERISM; SULFONAMIDES;

EID: 33846415837     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0608457     Document Type: Article

References (60)

1. Shapiro, S. D. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences. Curr. Opin. Cell Biol. 1998, 10, 602-608.
2. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, J. H. Design and Therapeutic application of matrix metalloproteinase inhibitors Chem. Rev. 1999, 99, 2735-2776.
3. Gijbels, K.; Galardy, R. E.; Steiman, L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of metalloproteases. J. Clin. Invest. 1994, 94, 2177-2182.
4. Chandler, S.; Coates, R.; Gearing, A.; Lury, J.; Wells, G.; Bone, E. Matrix metalloproteinase degrade myeline basic protein. Neurosci. Lett. 1995, 201, 223-226.
5. Steinman, L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996, 85, 299-302.
6. Hewson, A. K.; Smith, T.; Leonard, J. P.; Cuzner, M. L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor. Inflamm. Res. 1995, 44, 345-349.
7. Lohmander, L. S.; Hoerrner, L. A.; Lark, M. W. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial-fluid in human osteoarthritis. Arthritis Rheum. 1993, 36, 181-189.
8. Ahrens, D.; Koch, A. E.; Pope, R. M.; Stein-Picarella, M.; Niedbala, M. J. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum. 1996, 39, 1576-1587.
9. Blaser, J.; Friebel, S.; Maasjosthusmann, U.; Romisch, J.; Krahl-Mateblowski, U.; Freudenberg, W.; Fricke, R.; Tschesche, H. Detrmination in metalloproteinases. plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis. Clin. Chim. Acta 1996, 244, 17-33.
10. Ohishi, K.; Fujita, N.; Morinaga, Y.; Tsuruo, T. H-31 human breast cancer cells stimulate type 1 collagenase production in osteoblast-like cells and induce bone resorption. Clin. Exp. Metastasis 1995, 13, 287-295.
11. Witty, J. P.; Foster, S. A.; Stricklin, J. P.; Matrisian, L. M.; Stern, P. H. Parathyroid hormone-induced resorption in fetal rat limb bones is associated with production of the metalloproteinases collagenase and gelatinase B J. Bone Miner. Res. 1996, 11, 72-78.
12. Peress, N.; Perillo, E.; Zucker, S. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J. Neuropathol. Exp. Neurol. 1995, 54, 16-22.
13. Chang, C.; Werb, Z. The many faces of metalloproteinases: Cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 2001, 11, S37-S43.
14. Overall, C. M.; Lopez-Otin, C. Strategies for NMP inhibition in cancer: Innovations for the post-trial era. Nat. Rev. Cancer 2002, 2, 657-672.
15. Coussens, L. M. Fingleton, B.; Matrisan, L. M. Matrix metalloproteinases inhibitors and cancer: Trials and tribulations. Science 2002, 295, 2387-2392.
16. White, A. D. Emerging therapeutic advances for the development of second generation matrix metalloproteinase inhibitors. Curr. Pharm. Des. 1997, 3, 45-48.
17. Babine, R. E.; Bender, S. L. Molecular Recognition of protein-ligand complexes: Application to drug-design. Chem. Rev. 1997, 97, 1359-1472.
18. Puerta, D. T.; Cohen, S. M. A bioinorganic perspective of matrix metalloproteinase inhibition. Curr. Top. Med. Chem. 2004, 4, 1551-1573.
19. Matter, H.; Schudok, M. Recent advances in the design of matrix metalloproteinase inhibitors. Curr. Opin. Drug Discuss. 2004, 7, 513-535.
20. Bode, W.; Reinemer, P.; Huber, R.; Kleine, T. Schnierer, S.; Tschesche, H. The x-ray structure of catalytic domain of human neutrophil collagenase inhibited by a substrate analog reveals the essential for catalysis and specificity. EMBO J. 1994, 13, 1263-1269.
21. Lovejoy, B. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 1994, 263, 375-377.
22. Borkakoti, N.; Winkler, F. K.; Williams, D. H.; D'Arcy, A.; Broadhurst, M. J.; Brown, P. A.; Johnson, W. H.; Murray, E. J. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nature Struct. Biol. 1994, 1, 106-110.
23. Gooley, P. R.; O'Connell, J. F.; Marcy, A. The NMR structure of the inhibited catalytic domain of the human stromelysin-1 Nature Struct. Biol. 1994, 1, 111-118.
24. 1′ specificity pocket. Nature Struct. Biol. 1994, 1, 119-123.
25. Spurlino, J. C.; Smallwood, A. M.; Carlton, D. D.; Banks, T. M.; Vavra, K. J.; Johnson, J. S.; Cook, E. R.; Falvo, J.; Wahl, R. C. 1.56 A structure of mature truncated human fibroblast collagenase. Proteins: Struct. Funct. Genet. 1994, 19, 98-109.
26. Van Doren, S. R.; Kurochkin, A. V.; Hu, W.; Ye, Q.-Z.; Johnson, L. L.; Hupe, D. J.; Zuiderweg, E. R. P. Solution structure of the catalytic domain of human stromelysin complexed with a hydrophobic inhibitor. Protein Sci. 1994, 4, 2487-2498.
27. Gonnella, N.; Bohacek, R.; Zhang, X.; Kolossvary, L.; Paris, C. G.; Melton, R.; Winter, C.; Hu, S.-L.; Ganu, V. Bioactive conformation of stromelysin inhibitors determined by transferred nuclear Overhauser effect. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 462-466.
28. Dhanarai, V.; Ye, Q. Z.; Johnson, L. L.; Hupe, D. J.; Ortwine, D. F.; Dunbar, J. B., Jr.; Rubin, J. R.; Pavlovsky, A.; Humblet, C.; Blundell, T. L. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure 1996, 4, 375-386.
29. Moy, F. J.; Seddon, A.; Boehlen, P.; Powers, R. High resolution solution structure of basoc fibroblast prowth factor determined by multidimensional heteronuclear magnetic resonance spectroscopy. Biochemistry 1996, 35, 13552-13561.
30. Moy, F. J.; Chanda, P. K.; Chen, J. M.; Cosmi, S.; Edris, W.; Skotnicki, J. S.; Wilhelm, J.; Powers, R. NMR solution structure of the catalytic fragment of human fibroblast collagenase complexed with a sulphonamide derivative of a hydroxamic acid compound. Biochemistry 1999, 38, 7085-7096.
31. Lovejoy, B.; Welch, A. R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R. T.; Campbell, J. A.; Walker, K. A. M.; Martin, R.; Van Wart, H.; Browner, M. F. Crystal Structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nature Struct. Biol. 1999, 6, 217-221.
32. Zhang, X.; Gonnella, N.; Koehn, J.; Pathak, N.; Ganu, V.; Melton, R.; Parker, D.; Shu-Ih, H.; Ki-Yean, N. Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulphonamide inhibitor: binding comparison with stromelysin-1 and collagenase-1. J. Mol. Biol. 2000, 301, 513-524.
33. D'Alessio, S.; Gallina, C.; Gavuzzo, E.; Giordano, C.; Gorini, B.; Mazza, F.; Paradisi, M. P.; Panini, G.; Pochetti, G.; Sella, A. Inhibition of adamalysin II and MMPs by phosphonate analogues of snake venom peptides. Bioorg. Med. Chem. 1999, 7, 389-394.
34. Gavuzzo, E.; Pochetti, F.; Mazza, F.; Gallina, C.; Gorini, B.; D'Alessio, S.; Pieper, M.; Tschesche, H.; Tucker, P. A. Two crystal structures of human neutrophil collagenase, one complexed with a primed and the other with an unprimed-side inhibitor. Implications for drug design. J. Med. Chem. 2000, 43, 3377-3385.
35. Bianchini, G.; Aschi, M.; Cavicchio, G.; Crucianelli, M.; Preziuso, S.; Gallina, C.; Nastri, A.; Gavuzzo, E.; Mazza, F. Design, modelling synthesis and biological evaluation of peptidomimetic phosphinates as inhibitors of matrix metalloproteinases MMP-2 and MMP-8. Bioorg. Med. Chem. 2005, 13, 4740-4749.
36. Campestre, C.; Agamennone, M.; Tortorella, P.; Preziuso, S.; Biasone, A.; Gavazzo, E.; Pochetti, G.; Mazza, F.; Hiller, O.; Tschesche, H.; Consalvi, V.; Gallina, C. N-Hydroxyurea as zinc binding group in matrix maetalloproteinase inhibition: Mode of binding in a complex with MMP-8. Bioorg. Med. Chem. Lett. 2006, 16, 20-24.
37. Pochetti, G; Gavuzzo, E.; Campestre, C.; Agamennone, M.; Tortorella, P.; Consalvi, V.; Gallina, C.; Hiller, O.; Tschesche, H.; Tucker, P.; Mazza, F. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonate. J. Med. Chem. 2006, 49, 923-931.
38. Parker, M. H.; Ortwine, D. F.; O'Brien, P. M.; Lunney, E. A.; Banotai, C. A.; Mueller, W. T.; McConnell, P.; Brouillette, C. G. Stereoselective binding of an enantiomeric pair of stromelysin-1 inhibitors caused by conformational entropy factors. Bioorg. Med. Chem. Lett. 2000, 10, 2427-2430.
39. O'Brien, P. M.; Ortwine, D. F.; Pavlovsky, A. G.; Picard, J. A.; Sliskovic, D. R.; Roth, B. D.; Dyer, R. D.; Johnson, L. L.; Man, C. F.; Hallak, H. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J. Med. Chem. 2000, 43, 156-166.
40. Aschi, M.; Roccatano, D.; Di Nola, A.; Gallina, C.; Gavuzzo, E.; Pochetti, G.; Pieper, M.; Tschesche, H.; Mazza, F. Computational study of the catalytic domain of human neutrophil collagenase. Specific role of S3 and S′3 subsites in the interaction with a phosphonate inhibitor. J. Comput.-Aided Mol. Des. 2002, 16, 213-225.
41. Jarymowycz, V. A.; Stone, M. J. Fast time scale dynamics of protein backbones: NMR relaxation methods, application and functional consequences. Chem. Rev. 2006, 106, 1624-1671.
42. Adcock, S. A.; Mc Cammon, J. A. Molecular Dynamics: survey of methods for simulating the activity of proteins. Chem. Rev. 2006, 106, 1589-1615.
43. Stone, M. J. NMR relaxation studies of the role of conformational entropy in protein stability and ligand binding. Acc. Chem. Res. 2001, 34, 379-388.
44. Van der Spoel, D.; van Buren, A. R.; Apol, E.; Meulenhoff, P. J.; Tieleman, D. P.; Sijbers, A. L. T. M.; van Drunen, R.; Berendsen, H. J. C. Gromacs User Manual version 1.3, 1996.
45. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F. Hermans Interaction models for water in relation to protein hydration. In Intermolecular Forces; Pullman, B., Ed.; D. Reidel Publishing Company: Dordrecht, 1981; pp 331-342.
46. Amadei, A.; Chillemi, G.; Ceruso, M.; Grottesi, A.; Di Nola, A. Molecular dynamics simulations with constrained roto-translational motions: theoretical basis and statistical mechanical consistency. J. Chem. Phys. 2000, 112, 9-23.
47. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; Di Nola, A. Molecular Dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81, 3684-3690.
48. Hess, B.; Bekker, H.; Berendsen, H. J. C.; Frajie, J. G. E. M. LINCS: a linear constraint solver for molecular simulations. J. Comput. Chem. 1997, 18, 1463-1472.
49. Darden, T. A.; York, D. M.; Pedersen L. G. Particle mesh Ewald: method for Ewald sums in large systems. J. Chem. Phys. 1993, 98, 10089-10092.
50. van Gunsteren, W. F.; Billeter, S. R.; Eising, A. A.; Hunemberger, P. H.; Kruger, P.; Mark, A. E.; Scott, V. R. P.; Tironi, I. G. Biomolecular simulations: The GROMOS96 manual and user guide: vdf Hochschlverlag AG an der ETH Zurich: Zurich, 1996.
51. Breneman, C. M.; Wiberg, K. B. Determining atom-centered monopoles from molecular electrostatic potentials. J. Comput. Chem. 1990, 11, 361-367.
52. Parr, R. G.; Yang, W. Density functional theory of atoms and molecules; Oxford University Press: New York, 1989.
53. Schmidt, M. W.; Baldridge, K. K.; Boatz, J. A.; Elbert, S. T.; Gordon, M. S.; Jensen, J. J.; Koseki, S.; Matsunaga, N.; Nguyen, K. A.; Su, S.; Windus, T. L.; Dupuis, M.; Montgomery, J. A. General Atomic and Molecular Electronic Structure System J. Comput. Chem. 1993, 14, 1347-1363.
54. Amadei, A.; Linssen, A. B. M.; Berendsen, H. J. C. Essential dynamics of proteins. Proteins: Struct., Funct. Genet. 1993, 17, 412-425.
55. Stocker, W.; Grams, F.; Baumann, U.; Reinemer, P.; Gomis-Ruth, F. X.; McKay, D. B.; Bode, W. The metzincins: topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins define a superfamily of zinc-peptidases. Protein Sci. 1995, 4, 823-840.
56. Carney, C. F. F.; Ferrara, J. E.; Brunner, S. Methods for computing protein binding affinity J. Comput. Chem. 2005, 26, 243-251.
57. McCammon, J. A. Theory of biomolecular recognition Curr. Opin. Struct. Biol. 1998, 8, 245-249.
58. Simonson, T.; Archontis, G.; Karplus, M. Free energy simulation come of age: protein-ligand recognition. Acc Chem. Res. 2002, 35, 430-437.
59. Ajai, A.; Murcko, M. Computational methods to predict free energy in ligand receptor complexes. J. Med. Chem. 1998, 38, 4953-4967.
60. Swanson, J. M. J.; Henchman, R. H.; McCammon, J. A. Revisiting free energy calculations: a theoretical connection to MM/PBSA and direct calculation of the association free energy. Biophys. J. 2004, 86, 67-74.